
Gary P. Straub
Examiner (ID: 11985)
| Most Active Art Unit | 1103 |
| Art Unit(s) | 1103, 1754, 1106, 1801 |
| Total Applications | 1085 |
| Issued Applications | 776 |
| Pending Applications | 38 |
| Abandoned Applications | 271 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16870149
[patent_doc_number] => 20210163616
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/172694
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172694
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172694 | Binding agents binding to PD-L1 and CD137 and use thereof | Feb 9, 2021 | Issued |
Array
(
[id] => 16870148
[patent_doc_number] => 20210163615
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/168100
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71751
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/168100 | Chimeric antigen receptors targeting BCMA and methods of use thereof | Feb 3, 2021 | Issued |
Array
(
[id] => 17052241
[patent_doc_number] => 20210261675
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/164125
[patent_app_country] => US
[patent_app_date] => 2021-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -34
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17164125
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/164125 | CHIMERIC ANTIGEN RECEPTORS BASED ON SINGLE-DOMAIN ANTIBODIES AND METHODS OF USE THEREOF | Jan 31, 2021 | Pending |
Array
(
[id] => 18739638
[patent_doc_number] => 20230348600
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-02
[patent_title] => CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/795500
[patent_app_country] => US
[patent_app_date] => 2021-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 143638
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -153
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17795500
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/795500 | CD28 single domain antibodies and multivalent and multispecific constructs thereof | Jan 27, 2021 | Issued |
Array
(
[id] => 18237686
[patent_doc_number] => 20230069996
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => LIGAND-BINDING FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/793587
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793587
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793587 | Ligand-binding fusion proteins | Jan 19, 2021 | Issued |
Array
(
[id] => 17258562
[patent_doc_number] => 20210371547
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-02
[patent_title] => BIOLOGICAL PRODUCTS
[patent_app_type] => utility
[patent_app_number] => 17/151911
[patent_app_country] => US
[patent_app_date] => 2021-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 77
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17151911
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/151911 | BIOLOGICAL PRODUCTS | Jan 18, 2021 | Abandoned |
Array
(
[id] => 16885454
[patent_doc_number] => 20210171649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => B CELL MATURATION ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/150272
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30540
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150272
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150272 | B cell maturation antigen binding proteins | Jan 14, 2021 | Issued |
Array
(
[id] => 20788630
[patent_doc_number] => 12662535
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-23
[patent_title] => Pro-antibody that reduces off-target toxicity
[patent_app_type] => utility
[patent_app_number] => 17/150626
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 16
[patent_no_of_words] => 6392
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 100
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150626
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150626 | PRO-ANTIBODY THAT REDUCES OFF-TARGET TOXICITY | Jan 14, 2021 | Issued |
Array
(
[id] => 17611565
[patent_doc_number] => 20220153844
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => MULTISPECIFIC TREG BINDING MOLECULES
[patent_app_type] => utility
[patent_app_number] => 17/148337
[patent_app_country] => US
[patent_app_date] => 2021-01-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66569
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17148337
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/148337 | MULTISPECIFIC TREG BINDING MOLECULES | Jan 12, 2021 | Abandoned |
Array
(
[id] => 16749952
[patent_doc_number] => 20210101961
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods
[patent_app_type] => utility
[patent_app_number] => 17/121622
[patent_app_country] => US
[patent_app_date] => 2020-12-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14946
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17121622
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/121622 | Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods | Dec 13, 2020 | Abandoned |
Array
(
[id] => 16718492
[patent_doc_number] => 20210085639
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-25
[patent_title] => METHODS FOR PREVENTING ACUTE KIDNEY INJURY
[patent_app_type] => utility
[patent_app_number] => 17/112206
[patent_app_country] => US
[patent_app_date] => 2020-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19679
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -94
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17112206
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/112206 | Methods for preventing acute kidney injury | Dec 3, 2020 | Issued |
Array
(
[id] => 18093154
[patent_doc_number] => 20220411495
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-29
[patent_title] => POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/780068
[patent_app_country] => US
[patent_app_date] => 2020-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19872
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780068
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/780068 | POSITIVE ALLOSTERIC MODULATORS OF THE CALCIUM-SENSING RECEPTOR | Nov 26, 2020 | Abandoned |
Array
(
[id] => 20157003
[patent_doc_number] => 12383601
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-12
[patent_title] => Chimeric antigen receptors and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/104983
[patent_app_country] => US
[patent_app_date] => 2020-11-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 55
[patent_figures_cnt] => 86
[patent_no_of_words] => 127105
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 117
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17104983
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/104983 | Chimeric antigen receptors and uses thereof | Nov 24, 2020 | Issued |
Array
(
[id] => 17422412
[patent_doc_number] => 11255859
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-22
[patent_title] => Use of hexokinase-2 in detection of rare tumor cells in body fluid sample and kit
[patent_app_type] => utility
[patent_app_number] => 17/103190
[patent_app_country] => US
[patent_app_date] => 2020-11-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 15
[patent_no_of_words] => 8502
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17103190
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/103190 | Use of hexokinase-2 in detection of rare tumor cells in body fluid sample and kit | Nov 23, 2020 | Issued |
Array
(
[id] => 16688383
[patent_doc_number] => 20210070859
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => METHODS OF ASSESSING AND TREATING CANCER IN SUBJECTS HAVING DYSREGULATED LYMPHATIC SYSTEMS
[patent_app_type] => utility
[patent_app_number] => 17/096513
[patent_app_country] => US
[patent_app_date] => 2020-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096513
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/096513 | Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems | Nov 11, 2020 | Issued |
Array
(
[id] => 18058033
[patent_doc_number] => 20220389119
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
[patent_app_type] => utility
[patent_app_number] => 17/775063
[patent_app_country] => US
[patent_app_date] => 2020-11-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20101
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775063
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/775063 | ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES | Nov 5, 2020 | Pending |
Array
(
[id] => 16688389
[patent_doc_number] => 20210070865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => THERAPEUTIC CD47 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/084156
[patent_app_country] => US
[patent_app_date] => 2020-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 141
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084156
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/084156 | THERAPEUTIC CD47 ANTIBODIES | Oct 28, 2020 | Abandoned |
Array
(
[id] => 16837784
[patent_doc_number] => 20210145796
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/080195
[patent_app_country] => US
[patent_app_date] => 2020-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16829
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 1177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17080195
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/080195 | METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY | Oct 25, 2020 | Pending |
Array
(
[id] => 16711912
[patent_doc_number] => 20210079059
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => TREATMENT OF CANCER USING GFR ALPHA-4 CHIMERIC ANTIGEN RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 17/078903
[patent_app_country] => US
[patent_app_date] => 2020-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 85570
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17078903
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/078903 | Treatment of cancer using GFR alpha-4 chimeric antigen receptor | Oct 22, 2020 | Issued |
Array
(
[id] => 18126592
[patent_doc_number] => 20230012213
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-12
[patent_title] => NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2
[patent_app_type] => utility
[patent_app_number] => 17/770922
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14192
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17770922
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/770922 | Conjugation chemistry for catalytic antibody 38C2 | Oct 14, 2020 | Issued |